KFSH&RC Dedicado a Ser Pioneiro na Maximização do Valor dos Gastos com Saúde

RIADE, Arábia Saudita, May 12, 2024 (GLOBE NEWSWIRE) — O Dr. Majid Al Fayyadh, CEO do King Faisal Specialist Hospital and Research Centre (KFSH&RC) participa da Gulf Creatives Conference (GCC) at Harvard 2024. O evento, GCC at Harvard, é organizado pela The Diwan, uma organização dirigida por estudantes de pós–graduação da Universidade de Harvard. No seu discurso, o Dr. Al Fayyadh exibiu a jornada do KFSH&RC desde a sua criação em Riade há quase cinco décadas, mostrando como o hospital reduziu significativamente a necessidade de os pacientes viajarem para outros países para obterem cuidados médicos. O KFSH&RC passou a ser um prestador de serviços de saúde terciário de primeira linha e hoje oferece tratamentos de ponta para doenças cardíacas, tumores, transplante de órgãos e distúrbios genéticos.

O Dr. Al Fayyadh discutiu a transformação do KFSH&RC em uma fundação independente e sem fins lucrativos. Essa iniciativa, segundo ele, está alinhada com a visão estratégica da organização de se tornar líder global em inovação em saúde, enfatizando a excelência, inovação e investimento em tecnologia de ponta para enfrentar os desafios globais de saúde.

“A liderança saudita delineou uma visão clara para o KFSH&RC, estipulada por um decreto real de transição do hospital para uma fundação independente Sui Generis, sem fins lucrativos”, disse Sua Excelência, o Dr. Al Fayyadh.

Ele destacou ainda que essa transformação busca elevar os padrões globais de saúde por meio da maior independência e flexibilidade. Essa mudança permitirá que o KSFH&RC otimize os serviços existentes, busque novas oportunidades e direcione recursos para iniciativas que promovam a saúde e o bem–estar humanos dentro do Reino e no exterior. Em última análise, essa transição confirma a dedicação do KFSH&RC para com a excelência centrada no paciente.

O Dr. Al Fayyadh apontou que o KFSH&RC se vê como líder na maximização do valor dos gastos com saúde, aderindo a práticas baseadas em evidências para garantir ótimos resultados para os pacientes. O hospital busca permanecer na vanguarda da inovação global em saúde, com iniciativas destinadas a aumentar a equidade e o acesso à saúde em todo o mundo. Para conseguir isso, o KFSH&RC continuará a investir em instalações médicas de ponta, equipamentos avançados de diagnóstico, e tecnologias de tratamento de última geração. Com base no progresso existente em áreas como terapia com células CAR T, cirurgias robóticas, transplantes de órgãos e medicina personalizada, a instituição visa alcançar competitividade global. Isso será ainda mais apoiado pela promoção de uma força de trabalho excepcional, pela busca de avanços a nível do Prêmio Nobel e pelo fortalecimento de colaborações internacionais estratégicas.

O Dr. Al Fayyadh participou de um painel de discussão com foco no cenário em evolução do setor de saúde e nos resultados positivos da transformação contínua do KFSH&RC no atendimento ao paciente. Ele também abordou os desafios atuais e antecipou desenvolvimentos futuros no setor de saúde, enfatizando o profundo impacto das inovações do hospital no avanço global da saúde. Além disso, o Dr. Al Fayyadh destacou o papel eficaz das iniciativas transformadoras do hospital no alinhamento com os objetivos do Programa de Transformação do Setor de Saúde e da Saudi Vision 2030.

O KFSH&RC é reconhecido como uma das principais instituições mundiais pelo seu cuidado de saúde especializado, incentivo à inovação, sendo um hub avançado de pesquisa e educação médica avançada. Ele se dedica ao desenvolvimento de tecnologias médicas e aprimoramento dos padrões de cuidados em todo o mundo por meio de parcerias com as principais instituições locais, regionais e internacionais, para oferecer um serviço de classe mundial nos campos clínico, de pesquisa e educacional.

Pelo segundo ano consecutivo, o KFSH&RC manteve seu status de instituição líder no Reino, ocupando o 20º lugar mundial entre os 250 melhores centros médicos acadêmicos do mundo. Também foi reconhecido como a marca de saúde mais valiosa do Reino e do Oriente Médio em 2024, de acordo com a Brand Finance, e foi classificado entre os 250 melhores hospitais do mundo pela Newsweek Magazine.

Sobre o King Faisal Specialist Hospital and Research Centre :

O King Faisal Specialist Hospital & Research Centre é dos líderes globais de prestação de cuidados de saúde especializados, condução de inovação, e um hubs avançado de pesquisa e educação médica. Por meio de parcerias estratégicas com proeminentes instituições locais, regionais e internacionais, o hospital se dedica ao avanço de tecnologias médicas e elevação dos padrões de cuidado da saúde em todo o mundo.

O hospital conquistou sua posição como marca líder no setor de saúde em todo o Reino e Oriente Médio, marcando seu segundo ano consecutivo como a marca de saúde mais valiosa. Ele ocupa o 9º lugar no Reino e o 28º no Oriente Médio. O hospital se distingue como o único hospital do mundo a ser listado entre as 10 principais marcas do seu país, de acordo com dois relatórios da “Brand Finance” sobre as 50 marcas mais valiosas da Arábia Saudita e as 150 marcas mais valiosas do Oriente Médio em 2024.

Devido aos programas de transformação e à Vision 2030 do Reino, lançados por Sua Alteza Real o Príncipe Herdeiro e pelo Primeiro–Ministro – que Deus o proteja – para aumentar a liderança do Reino no setor global de saúde, o KFSH&RC surgiu como um dos principais Centros Médicos Acadêmicos do Oriente Médio e da África. Ele permaneceu em 20º lugar no mundo pelo segundo ano consecutivo em 2024, de acordo com o “Brand Finance”. Além disso, ele foi classificado entre os melhores hospitais do mundo em 2024 pela revista americana “Newsweek”.

Para mais informações, contate:

Sr. Essam AlZahrani, Dirigente Interino de Assuntos de Mídia, 0555254429

Sr. Abdullah Alown, Editor Sênior de Mídia, 0556294232

Fotos deste comunicados disponíveis em:
https://www.globenewswire.com/NewsRoom/AttachmentNg/d9d0ed27–fa87–49ac–b72b–ccf5b5843637
https://www.globenewswire.com/NewsRoom/AttachmentNg/682fadee–20a5–4328–bf00–e036bc3350fd 


GLOBENEWSWIRE (Distribution ID 9115946)

Le KFSH&RC s’efforce d’être un pionnier dans la valorisation optimale des dépenses de santé

RIYAD, Arabie saoudite, 12 mai 2024 (GLOBE NEWSWIRE) — Le Dr Majid Al Fayyadh, directeur de l’hôpital spécialisé et centre de recherche King Faisal, ou KFSH&RC pour King Faisal Specialist Hospital and Research Centre, a rejoint la conférence Gulf Creatives 2024, organisée à Harvard. L’organisation de cet événement est assurée par The Diwan, un collectif dirigé par des étudiants diplômés de la célèbre université. Dans son discours, le Dr Al Fayyadh a présenté la trajectoire du KFSH&RC depuis sa création à Riyad il y a presque cinquante ans, mettant en avant comment il est parvenu à réduire considérablement la nécessité de se rendre à l’étranger pour les patients en quête de soins médicaux. L’hôpital spécialisé et centre de recherche King Faisal est aujourd’hui un prestataire de santé de premier ordre qui propose des solutions de pointe pour le traitement des maladies cardiaques, des tumeurs, des greffes d’organes et des troubles génétiques.

Le Dr Al Fayyadh a également évoqué la transformation de l’établissement en une fondation indépendante à but non lucratif. Cette démarche, a–t–il indiqué, s’inscrit dans la vision stratégique de l’hôpital à devenir un leader mondial de l’innovation au service de la santé, en focalisant les efforts sur l’excellence, l’innovation et les investissements dans la technologie de pointe pour relever les enjeux de santé à l’échelle mondiale.

« Les instances leader du royaume ont établi un objectif clair pour le KFSH&RC, sous mandat d’un décret royal faisant converger l’hôpital en une fondation indépendante en genre propre, et à but non lucratif » explique Son Excellence le Dr Al Fayyadh. 

A souligné par ailleurs que cette transformation vise à relever les normes internationales applicables aux soins de santé au profit de plus d’indépendance et de flexibilité. Cette évolution statutaire permettra au KFSH&RC d’optimiser les services existants, de poursuivre de nouvelles opportunités et d’axer ses ressources sur des initiatives jouant en faveur de la santé et du bien–être humain au sein du royaume et à l’échelle internationale. En fin de compte, cette initiative renforce l’engagement du KFSH&RC envers l’excellence centrée sur le patient.

Le Dr Al Fayyadh a observé que le KFSH&RC se considère comme un leader de la valorisation optimale des dépenses de santé, en adoptant des pratiques fondées sur des preuves aux fins de garantir les meilleurs résultats pour les patients. Il cherche à rester à l’avant–garde de l’innovation mondiale en matière de santé en pilotant des initiatives conçues pour accroître l’équité en matière de santé et l’accès aux soins dans le monde entier. À cet effet, l’hôpital poursuivra ses investissements dans des installations médicales de pointe, des outils de diagnostic avancés et des technologies de traitement de pointe. En s’appuyant sur les progrès réalisés dans des domaines tels que la thérapie cellulaire CAR T, les opérations chirurgicales robotisées, les greffes d’organes et la médecine personnalisée, l’institution aspire atteindre une compétitivité mondiale. Elle y parviendra d’autant mieux en privilégiant l’embauche d’un personnel exceptionnel, en poursuivant des percées dignes d’un prix Nobel et en renforçant les collaborations internationales stratégiques.

Le Dr Al Fayyadh a participé à une table ronde et y a souligné l’évolution du paysage de la santé et les résultats positifs issus de la transformation permanente des soins aux patients apportés par le KFSH&RC. Il a également abordé les enjeux actuels et les développements de demain qui se dessinent au sein du secteur de la santé, en insistant sur les effets prononcés des innovations de l’hôpital sur l’évolution de la santé mondiale. Enfin, le Dr Al Fayyadh a mis en lumière l’efficacité propre aux desseins de transformation de l’hôpital au double regard des objectifs du programme royal de transformation du secteur de la santé et du projet « Saudi Vision 2030 ».

Le KFSH&RC est reconnu parmi les principales institutions du monde à fournir des soins de santé spécialisés, à incarner l’innovation et à faire acte de centre de recherche médicale et d’éducation avancé. L’hôpital se consacre au développement de technologies médicales et au relèvement du niveau des soins de santé dans le monde entier, en forgeant des partenariats avec des institutions locales, régionales et internationales de premier plan pour atteindre les meilleures pratiques dans les domaines cliniques, de recherche et d’éducation.

Pour la deuxième année consécutive, le KFSH&RC a été consacré au titre de la première institution du royaume et se classe à la 20e position du classement mondial distinguant les 250 principaux centres médicaux universitaires du monde. Son empreinte est également reconnue au titre de la marque de santé la plus valorisée du royaume et du Moyen–Orient en 2024, selon Brand Finance, et le magazine Newsweek l’a classé parmi les 250 meilleurs hôpitaux du monde.

À propos de l’hôpital spécialisé et centre de recherche King Faisal :

Le King Faisal Specialist Hospital & Research Centre fait partie des leaders mondiaux en matière de soins de santé spécialisés, et d’innovation, servant de centre de formation et de recherche médicale avancée. Grâce à des partenariats stratégiques avec d’éminents établissements locaux, régionaux et internationaux, l’hôpital se consacre à l’avancement des technologies médicales et à l’élévation des normes de soins de santé dans le monde entier.

L’hôpital a conforté sa position de leader du secteur de la santé en Arabie saoudite et au Moyen–Orient, en se voyant décerner pour la deuxième année consécutive le titre de marque de santé la plus valorisée. Il se classe 9e du royaume et 28e au Moyen–Orient. L’hôpital se distingue en étant le seul hôpital du monde à figurer au top 10 des marques de son pays, comme le soulignent deux rapports de « Brand Finance » consacrés aux 50 meilleures marques d’Arabie saoudite et aux 150 meilleures marques du Moyen–Orient en 2024, respectivement.

En raison des programmes de transformation et du projet royal « Saudi Vision 2030 » initié par Son Altesse Royale le Prince Héritier et Premier Ministre – que Dieu le préserve – pour renforcer le leadership du royaume dans le secteur de la santé mondiale, le KFSH&RC est devenu un centre médical universitaire de première importance dans la région MENA. En 2024, il s’est classé au 20e rang mondial pour la deuxième année consécutive selon « Brand Finance », et s’est également distingué parmi les 250 meilleurs hôpitaux du monde selon le magazine américain « Newsweek » cette même année.

Pour tout complément d’information, veuillez contacter :

M. Essam AlZahrani, Responsable des affaires médiatiques, 0555254429

M. Abdullah Alown, Coordinateur médias, 0556294232

Les photos jointes au présent communiqué sont disponibles aux adresses suivantes :
https://www.globenewswire.com/NewsRoom/AttachmentNg/d9d0ed27–fa87–49ac–b72b–ccf5b5843637
https://www.globenewswire.com/NewsRoom/AttachmentNg/682fadee–20a5–4328–bf00–e036bc3350fd

 


GLOBENEWSWIRE (Distribution ID 9115946)

KFSH&RC strebt Vorreiterrolle bei der Maximierung der Ausgaben für das Gesundheitswesen an

RIAD, Saudi–Arabien, May 12, 2024 (GLOBE NEWSWIRE) — Dr. Majid Al Fayyadh, CEO des King Faisal Specialist Hospital and Research Centre (KFSH&RC), hat an der Gulf Creatives Conference (GCC) in Harvard 2024 teilgenommen. Die Veranstaltung, GCC at Harvard, wird von The Diwan organisiert, einer Organisation, die von Studirenden der Harvard University geleitet wird. In seiner Ansprache stellte Dr. Al Fayyadh die Entwicklung des KFSH&RC seit seiner Gründung in Riad vor fast fünf Jahrzehnten dar und hob hervor, wie es die Notwendigkeit für Patienten, zur medizinischen Versorgung ins Ausland zu reisen, erheblich verringert hat. Das KFSH&RC hat sich zu einem führenden Anbieter von tertiären Gesundheitsdiensten entwickelt und bietet heute hochmoderne Behandlungen für Herzkrankheiten, Tumore, Organtransplantationen und genetische Störungen an.

Dr. Al Fayyadh erläuterte die Umwandlung von KFSH&RC in eine unabhängige, gemeinnützige Stiftung. Dieser Schritt stehe im Einklang mit der strategischen Vision der Organisation, ein globaler Innovationsführer im Gesundheitswesen zu werden, der sich auf Spitzenleistungen, Innovation und Investitionen in Spitzentechnologie konzentriert, um die globalen gesundheitlichen Herausforderungen zu bewältigen.

„Die saudische Führung hat eine klare Vision für das KFSH&RC skizziert, die durch einen königlichen Erlass umgesetzt wird, der das Krankenhaus in eine unabhängige, gemeinnützige Stiftung sui generis umwandelt“, erklärte Seine Exzellenz Dr. Al Fayyadh.

Er betonte ferner, dass diese Umgestaltung darauf abzielt, die globalen Standards im Gesundheitswesen durch größere Unabhängigkeit und Flexibilität anzuheben. Diese Verlagerung wird es dem KSFH&RC ermöglichen, bestehende Dienstleistungen zu optimieren, neue Möglichkeiten zu verfolgen und Ressourcen auf Initiativen zu lenken, die die Gesundheit und das Wohlergehen der Menschen sowohl im Königreich als auch international fördern. Letztlich unterstreicht dieser Schritt das Engagement des KFSH&RC für patientenorientierte Spitzenleistungen.

Dr. Al Fayyadh wies darauf hin, dass das KFSH&RC eine führende Rolle bei der Maximierung des Nutzens von Gesundheitsausgaben anstrebt und sich dabei an evidenzbasierte Verfahren hält, um optimale Patientenergebnisse zu gewährleisten. Mit Initiativen zur Verbesserung der gesundheitlichen Chancengleichheit und des Zugangs zur Gesundheitsversorgung auf der ganzen Welt will es weiterhin eine Vorreiterrolle in der globalen Gesundheitsversorgung einnehmen. Um dies zu erreichen, wird das KFSH&RC weiterhin in modernste medizinische Einrichtungen, fortschrittliche Diagnosegeräte und modernste Behandlungstechnologien investieren. Aufbauend auf den bereits erzielten Fortschritten in Bereichen wie CAR–T–Zell–Therapie, Roboterchirurgie, Organtransplantation und personalisierte Medizin strebt die Einrichtung eine globale Wettbewerbsfähigkeit an. Dies wird durch die Förderung außergewöhnlicher Arbeitskräfte, die Erzielung von Durchbrüchen in der Größenordnung des Nobelpreises und die Stärkung strategischer internationaler Kooperationen weiter unterstützt werden.

Dr. Al Fayyadh nahm an einer Podiumsdiskussion teil, die sich mit der sich verändernden Landschaft des Gesundheitssektors und den positiven Ergebnissen der laufenden Umgestaltung der Patientenversorgung durch das KFSH&RC befasste. Er sprach auch über aktuelle Herausforderungen und voraussichtliche künftige Entwicklungen im Gesundheitssektor und betonte die tiefgreifenden Auswirkungen der Innovationen des Krankenhauses auf den weltweiten Fortschritt im Gesundheitswesen. Darüber hinaus betonte Dr. Al Fayyadh die effektive Rolle der transformativen Initiativen des Krankenhauses bei der Ausrichtung auf die Ziele des Programms zur Transformation des Gesundheitssektors und der saudischen Vision 2030.

Das KFSH&RC ist als eine der weltweit führenden Einrichtungen anerkannt, die spezialisierte Gesundheitsversorgung anbieten, Innovationen vorantreiben und als Zentrum für medizinische Forschung und Ausbildung dienen. Die Einrichtung widmet sich der Entwicklung medizinischer Technologien und der Anhebung der Standards im Gesundheitswesen weltweit, indem sie Partnerschaften mit führenden lokalen, regionalen und internationalen Einrichtungen eingeht, um erstklassige Dienstleistungen in den Bereichen Klinik, Forschung und Ausbildung zu erbringen.

Im zweiten Jahr in Folge hat das KFSH&RC seinen Status als führende Einrichtung im Königreich beibehalten und rangiert weltweit auf Platz 20 unter den 250 besten akademischen medizinischen Zentren der Welt. Laut Brand Finance ist es außerdem die wertvollste Marke im Gesundheitswesen des Königreichs und des Nahen Ostens im Jahr 2024 und wurde vom Newsweek Magazine in die Liste der 250 besten Krankenhäuser der Welt aufgenommen.

Über das King Faisal Specialist Hospital and Research Centre:

Das King Faisal Specialist Hospital & Research Centre ist weltweit führend in der Bereitstellung spezialisierter Gesundheitsversorgung, treibt Innovationen voran und dient als Zentrum für medizinische Forschung und Ausbildung. Durch strategische Partnerschaften mit prominenten lokalen, regionalen und internationalen Institutionen engagiert sich das Krankenhaus für die Weiterentwicklung medizinischer Technologien und die Anhebung der Gesundheitsstandards weltweit.

Das Krankenhaus hat seine Position als führende Marke im Gesundheitssektor des Königreichs und des Nahen Ostens gefestigt und wurde zum zweiten Mal in Folge zur wertvollsten Marke im Gesundheitswesen gekürt. Innerhalb des Königreichs liegt es auf Platz 9 und im Nahen Osten auf Platz 28. Das Krankenhaus zeichnet sich als einziges Krankenhaus weltweit dadurch aus, dass es in die Top 10 der Marken seines Landes aufgestiegen ist, was in zwei Berichten von „Brand Finance” über die 50 wertvollsten Marken in Saudi–Arabien und die 150 wertvollsten Marken im Nahen Osten im Jahr 2024 hervorgehoben wird.

Dank der Transformationsprogramme und der Vision 2030 des Königreichs, die von Seiner Königlichen Hoheit dem Kronprinzen und Premierminister – möge Gott ihn beschützen – ins Leben gerufen wurden, um die Führungsrolle des Königreichs im globalen Gesundheitssektor zu stärken, hat sich das KFSH&RC zu einem führenden akademischen medizinischen Zentrum im Nahen Osten und in Afrika entwickelt. Laut „Brand Finance” bleibt es 2024 zum zweiten Mal in Folge auf Platz 20 der Weltrangliste Außerdem wurde es von der amerikanischen Zeitschrift „Newsweek” zu den 250 besten Krankenhäusern weltweit im Jahr 2024 gezählt.

Für weitere Informationen wenden Sie sich bitte an:

Hr. Essam AlZahrani, Acting Head of Media Affairs, 0555254429

Hr. Abdullah Alown, Media Coordination Officer, 0556294232

Fotos zu dieser Mitteilung sind verfügbar unter:
https://www.globenewswire.com/NewsRoom/AttachmentNg/d9d0ed27–fa87–49ac–b72b–ccf5b5843637
https://www.globenewswire.com/NewsRoom/AttachmentNg/682fadee–20a5–4328–bf00–e036bc3350fd


GLOBENEWSWIRE (Distribution ID 9115946)

AUTODESK INVESTOR NEWS: ROSEN, THE FIRST FILING FIRM, Encourages Autodesk, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – ADSK

NEW YORK, May 12, 2024 (GLOBE NEWSWIRE) —

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Autodesk, Inc. (NASDAQ: ADSK) between June 1, 2023 and April 16, 2024, both dates inclusive (the “Class Period”), of the important June 24, 2024 lead plaintiff deadline in the securities class action first filed by the Firm.

SO WHAT: If you purchased Autodesk securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Autodesk class action, go to https://rosenlegal.com/submit–form/?case_id=24019 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email case@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than June 24, 2024. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made materially false and/or misleading statements and/or failed to disclose that: (1) Autodesk, Inc. lacked adequate internal controls as a result of issues with its free cash flow and non–GAAP operating margin practices; and (2) as a result, defendants’ statements about its business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Autodesk class action, go to https://rosenlegal.com/submit–form/?case_id=24019 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email case@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the–rosen–law–firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm’s attorneys are ranked and recognized by numerous independent and respected sources. Rosen Law Firm has secured hundreds of millions of dollars for investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40thFloor
New York, NY 10016
Tel: (212) 686–1060
Toll Free: (866) 767–3653
Fax: (212) 202–3827
case@rosenlegal.com
www.rosenlegal.com 


GLOBENEWSWIRE (Distribution ID 9115828)

ALTIMMUNE INVESTOR NEWS: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ALT

NEW YORK, May 12, 2024 (GLOBE NEWSWIRE) —

WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Altimmune, Inc. (NASDAQ: ALT) between December 1, 2023 and April 26, 2024, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 5, 2024.

SO WHAT: If you purchased Altimmune securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Altimmune class action, go to https://rosenlegal.com/submit–form/?case_id=22535 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email case@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 5, 2024. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Altimmune overstated the potential for its lead product candidate, pemvidutide, a glucagon–like peptide–1 (“GLP–1”), to stand out from competing GLP–1 agonists based on the drug’s efficacy and tolerability results observed in evaluating pemvidutide for the treatment of obesity (the “MOMENTUM Trial”); (2) accordingly, the MOMENTUM trial results were less significant to pemvidutide’s clinical, commercial, and competitive prospects than defendants had led investors to believe; (3) as a result of all the foregoing, defendants had overstated Altimmune’s prospects for finding a strategic partner to develop pemvidutide; and (4) as a result, Altimmune’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Altimmune class action, go to https://rosenlegal.com/submit–form/?case_id=22535 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email case@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the–rosen–law–firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686–1060
Toll Free: (866) 767–3653
Fax: (212) 202–3827
case@rosenlegal.com
www.rosenlegal.com 


GLOBENEWSWIRE (Distribution ID 9115827)

ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages bluebird bio Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – BLUE

NEW YORK, May 12, 2024 (GLOBE NEWSWIRE) —

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of bluebird bio, Inc. (NASDAQ: BLUE) between April 24, 2023 and December 8, 2023, both dates inclusive (the “Class Period”), of the important May 28, 2024 lead plaintiff deadline.

SO WHAT: If you purchased bluebird common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the bluebird class action, go to https://rosenlegal.com/submit–form/?case_id=23717 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email case@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 28, 2024. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants made false and/or misleading statements. Specifically, defendants created the false impression that: (1) bluebird could obtain Federal Drug Administration (“FDA”) approval for lovo–cel, a gene therapy for sickle cell patients, without any black box warnings for haematological malignancies; (2) bluebird would be granted a priority review voucher by the FDA and in turn sell it in order to strengthen bluebird’s financial position for the lovo–cel launch; (3) as a result, bluebird had significantly overstated Lyfgenia’s clinical and/or commercial prospects; and (4) therefore, bluebird’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the bluebird class action, go to https://rosenlegal.com/submit–form/?case_id=23717 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email case@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the–rosen–law–firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686–1060
Toll Free: (866) 767–3653
Fax: (212) 202–3827
case@rosenlegal.com
www.rosenlegal.com


GLOBENEWSWIRE (Distribution ID 9115823)

VXX DEADLINE ALERT: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Barclays PLC Investors to Secure Counsel Before Important May 20 Deadline in Securities Class Action – VXX

NEW YORK, May 12, 2024 (GLOBE NEWSWIRE) —

WHY: Rosen Law Firm, a global investor rights law firm, reminds acquirers of a short position in Barclays’ iPath Series B S&P 500 VIX Short–Term Futures Exchange Traded Note (“ETN”) under the symbol “VXXB” (hereinafter “VXX”) due to selling VXX ETNs, selling VXX call options, and/or buying VXX put options and who held that position as of the close of market on March 13, 2022, of the important May 20, 2024 lead plaintiff deadline.

The case is against Barclays PLC, Barclays Bank PLC, James E. Staley, Tushar Morzaria, and C.S. Venkatakrishnan (together, “Defendants”).

SO WHAT: If you acquired a short position of VXX ETNs you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Barclays class action, go to https://rosenlegal.com/submit–form/?case_id=23523 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email case@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 20, 2024. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, Barclays failed to inform investors and the market that it had not implemented any internal controls to monitor the issuances of securities from its shelf registrations, and that it had issued and sold billions of dollars of unregistered securities, including VXX ETNs, in violation of the federal securities registration laws. Barclays illegally sold over $17 billion of unregistered securities over approximately 18 months. Once its misconduct came to light, Barclays had to suddenly and without warning suspend any further issuances and sales of new VXX ETNs. This suspension of sales, which was announced just before the market opened on March 14, 2022, caused the market price of VXX to skyrocket and investors who were short VXX to suffer substantial losses.

To join the Barclays class action, go to https://rosenlegal.com/submit–form/?case_id=23523 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email case@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the–rosen–law–firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

———————————————–

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686–1060
        Toll Free: (866) 767–3653
        Fax: (212) 202–3827
        case@rosenlegal.com
        www.rosenlegal.com


GLOBENEWSWIRE (Distribution ID 9115832)

AXTI INVESTOR NEWS: ROSEN, A LEADING LAW FIRM, Encourages AXT, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – AXTI

NEW YORK, May 12, 2024 (GLOBE NEWSWIRE) —

WHY: Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of AXT, Inc. (NASDAQ: AXTI) between March 24, 2021 and April 3, 2024, both dates inclusive (the “Class Period”). A class action has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 5, 2024 in the securities class action first filed by the Firm.

SO WHAT: If you purchased AXT securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the AXT, Inc. class action, go to https://rosenlegal.com/submit–form/?case_id=24168 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email case@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 5, 2024. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made materially false and/or misleading statements and/or failed to disclose that: (1) AXT, Inc. overstated its property holdings; (2) AXT, Inc. did not disclose that the attempted listing of an AXT, Inc. subsidiary in China had reportedly failed; (3) AXT, Inc. routinely engaged in environmental violations and unsafe business practices; (4) AXT’s production declined in 2023; and (5) as a result, defendants’ statements about its business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the AXT, Inc. class action, go to https://rosenlegal.com/submit–form/?case_id=24168 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email case@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the–rosen–law–firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm’s attorneys are ranked and recognized by numerous independent and respected sources. Rosen Law Firm has secured hundreds of millions of dollars for investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

———————————————–

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686–1060
        Toll Free: (866) 767–3653
        Fax: (212) 202–3827
        case@rosenlegal.com
        www.rosenlegal.com


GLOBENEWSWIRE (Distribution ID 9115830)